CytoVeris is a biotech developing guided surgery tools for tumor removal.
CytoVeris has been founded with the vision to develop new optical based ‘guided surgery’ probes to allow surgical oncologists to identify and remove all tumor tissue in real-time during cancer resection surgery, thereby improving the surgeon’s ability to ensure clean margins are attained.
CytoVeris was founded in 2018 by Alan Kersey. The company is headquartered in Farmington, Connecticut.
CytoVeris is developing a tumor scanner called TumorMAP and a platform called OncoVeris. Its technology, which uses an optical technique called Raman spectroscopy that can use a laser to probe tissue several millimeters deep.
CytoVeris is also developing additional optical approaches that assess biochemical and structural indicators of cancer in the tissue and its micro-environment that will augment Raman margin assessment for improved specificity and sensitivity, as well as provide additional insight into tissue characteristics.
CytoVeris has raised $3.7M in a new round of funding on April 29, 2020. This brings CytoVeris' total funding to $7.4M to date.